Stock QuotesEurobonds ($)
NIGERIAN EUROBONDS June 30, 2020: 6.75% $500M Jan 2021 – 101.386/4.265%,   5.625% $300M Jun 2022 – 101.390/4.882%,   6.375% $500M Jul 2023 – 101.902/5.682%,   7.625% $1.118BN Nov 2025 – 102.427/7.073%,   6.500% $1.50BN Nov 2027 – 95.161/7.358%,   7.143% $1.25BN FEB 2030 – 93.514/ 8.124%, 8.747% $1.0BN Jan 2031 – 100.184/ 8.719%,   7.875% $1.50BN Feb 2032 – 94.401/8.646%,   7.696% $1.25BN Feb 2038 – 91.535/ 8.638%,   7.625% $1.50BN Nov 2047 – 89.616/8.617%,   9.248% $750M Jan 2049 – 101.337/9.115%.
Business Finance Info & Updates

AIICO Insurance Plc proposed dividend

1 Stanbic IBTC Holdings Plc: The Company notified The Exchange of the
following Executive Management promotions:
i) Promotion of Dr. Demola Sogunle to Chief Executive, Stanbic IBTC
Holdings Plc.
ii) Promotion of Mr. Wole Adeniyi to the Chief Executive position in
Stanbic IBTC Bank Plc.
iii) Promotion of Mr. Remy Osuagwu to Executive Director, Personal and
Business Banking
All the aforementioned above, await regulatory approval.

2 Fidson Healthcare Plc: Proposed dividend: N0.15k; Proposed bonus: Nil
Qualification date: July 06, 2020; Closure date: July 07 – 13, 2020; Payment
date; July 24, 2020; AGM date: July 23, 2020; AGM venue: Conference Centre
2nd Floor, Fidson Towers, 268 Ikorodu Road, Obanikoro, Lagos.

3 AIICO Insurance Plc (Revised): Proposed dividend: Nil; Proposed bonus:1
for every 5 shares held; Qualification date: September 23, 2020; Closure date:
September 24 – 29, 2020.

4 Omoluabi Mortgage Bank Plc: The Bank notified The Exchange of the
following Executive and Non-Executive appointments:
i) Appointment of Mr. Yemi Adefisan as a Non-Executive Director.
ii) Appointment of Mrs. Fehintola Ibidunni Olatunde-Agbeja as an Independent
Director.
iii) Appointment of Mr. Olufemi Adesina as a Non-Executive Director.
iv) Appointment of Mr. Adewole Adeniran as a Non-Executive Director.
v) Appointment of Mr. Oyewole Olowu as an Executive Director.
vi) Appointment of Mr. Adewole Adekunle as the Managing Director.
All the aforementioned above, await regulatory approval.

Leave a Reply

Your email address will not be published. Required fields are marked *

CAPTCHA ImageChange Image